Diabetes Archives

News and Trends 19 Oct 2022

CDF15 cytokine a promising therapeutic target against type 2 diabetes

CDF15 cytokine a promising therapeutic target against type 2 diabetes Researchers have conducted a review study on growth differentiation factor 15 (GDF15) — a protein expressed under physiological stress conditions — and its potential impact on the treatment for type 2 diabetes. It was led by Professor Manuel Vázquez-Carrera, from the Faculty of Pharmacy and […]

October 19, 2022 - 5 minutesmins - By Jim Cornall

Best in Biotech 7 Oct 2022

Needle-free diabetes care: 7 devices that painlessly monitor blood sugar

Will the daily routine of finger pricking to monitor blood sugar levels finally come to an end for the millions living with diabetes? Diabetes affects over 537 million adults worldwide. People with diabetes have to test their blood sugar levels several times a day, usually by pricking their finger with a lancet. This can be […]

October 7, 2022 - 6 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Sep 2022

Beyond Biotech podcast 16: Adocia, Omnio, Phenomix Sciences, Tridek-One

This week, we have four guests: Olivier Soula, deputy-CEO and director of R&D at Adocia; Ulrika Norin, CEO of Omnio; Mark Bagnall, CEO of Phenomix Sciences; and Laurence de Schoulepnikoff, CEO of Tridek-One. We also have our weekly chat with global commercial real estate services company JLL, with Travis McCready. This week’s podcast is sponsored […]

September 30, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 28 Sep 2022

Ilya Pharma enrols first patient in diabetic foot ulcer study

Ilya Pharma AB says the first patients have been enrolled in a phase II study for its lead candidate ILP100-Topical in patients with diabetic foot ulcers. Overall, up to 13% of patients with diabetes mellitus of any type develop non-healing ulcers, a physical and psychological disabling condition, where infection of such wound results in a […]

September 28, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 22 Sep 2022

New phase 1 biomarker results reported by Glyscend Therapeutics for diabetes drug

A U.S.-based biotech yesterday (September 21) reported additional biomarker results for a treatment of type 2 diabetes (T2D) from a phase 1 study. Glyscend Therapeutics, has been looking at orally administered drug GLY-200, which is a gut-restricted therapeutic. The company also received clearance from the U.S. Food and Drug Administration (FDA) on an Investigational New […]

September 22, 2022 - 4 minutesmins - By Liza Laws

News and Trends 20 Sep 2022

Positive results from Arecor Therapeutics’ clinical trial of rapid, concentrated insulin

Arecor Therapeutics today (September 20) announced positive results from a phase 1 clinical trial of its rapid, concentrated insulin product. The company’s candidate named AT278 is formulated using its Arestat technology and designed to significantly accelerate insulin absorption post injection. This is to enable more effective and convenient management of blood glucose levels in people […]

September 20, 2022 - 2 minutesmins - By Liza Laws

News and Trends 19 Sep 2022

CellResearch Corporation announces positive results of phase I diabetic foot ulcer study

CellResearch Corporation, a Singapore-based biopharma company says it has successfully closed the first phase I study for CorLiCyte, a stem cell therapy derived from umbilical cord lining stem cells, with research partners at the University of Colorado, Anschutz Medical Campus and ClinImmune Cell and Gene Therapy. CorLiCyte is in development for the treatment of serious […]

September 19, 2022 - 3 minutesmins - By Jim Cornall

More News! 16 Sep 2022

Strategic collaboration for drug to treat NASH, obesity and diabetes announced

A conditional and exclusive license agreement to develop and commercialize a drug to treat nonalcoholic steatohepatitis (NASH), obesity and type 2 diabetes has been agreed. NeuroBo Pharmaceuticals and Dong-A ST Co., announced their strategic collaboration today (September 16) for DA-1241 and DA-1726 which are currently being evaluated for treatment. DA-1241 is a novel G-Protein-Coupled Receptor […]

September 16, 2022 - 4 minutesmins - By Liza Laws

News and Trends 7 Sep 2022

Adocia takes steps with implants for treatment of type 1 diabetes

French biopharma company Adocia has established a first proof of concept for its AdoShell Islets implant by achieving glycemic control without insulin injections in immunocompetent diabetic rats during a 132-day study. AdoShell Islets is an immuno-protective synthetic biomaterial containing islets of Langerhans. After implantation in diabetic animals, the islets encapsulated in AdoShell secrete insulin in […]

September 7, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 1 Sep 2022

Provention Bio looks to advance diabetes drug through $125M loan

U.S. biopharma company Provention Bio, Inc. has secured a term loan facility of up to $125 million with Hercules Capital, Inc. ahead of the company’s potential launch of teplizumab. The BLA for teplizumab, Provention Bio’s lead investigational drug candidate, for the delay of progression to stage 3 clinical type 1 diabetes in at-risk individuals has […]

September 1, 2022 - 2 minutesmins - By Jim Cornall

francine kaufman senseomics diabetes management

Opinion 1 Sep 2022

The evolution of diabetes management

Diabetes management has progressed leaps and bounds in the last 100 years. Francine Kaufman, Chief Medical Officer of Senseonics, outlines how far the field has progressed and what is on the horizon for diabetes patients. This year marks 100 years since insulin was first available to treat diabetes – an incredible milestone. One of the […]

September 1, 2022 - 6 minutesmins - By External Contributor

News and Trends 2 Aug 2022

Enrollment completed for trial looking at treatment of diabetic kidney disease

Enrollment has been completed for a study of a regenerative cell therapy investigational product for intra-renal artery administration to treat diabetic kidney disease (DKD). U.S.-based Caladrius Biosciences Inc., a clinical-stage biopharma company that develops therapies designed to treat or reverse disease, made the announcement today (August 2). The phase 1b open-label, proof-of-concept study will look […]

August 2, 2022 - 2 minutesmins - By Liza Laws

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us